drugset / Trial / NCT00429858
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Phase 2
Terminated
21 enrolled
Andrew Ko
Eli Lilly and Company · collabTaiho Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying gene expression in predicting treatment response in patients receiving gemcitabine and S-1 for locally advanced unresectable or metastatic pancreatic cancer.
Timeline
- Start
- 2007-01-22
- Primary completion
- 2010-01-20
- Completion
- 2010-01-20
Outcome
Outcome not reported
Stopped (Enrollment): “Study accrual rate is very slow, it was mandated by NCI to be terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 25 mg/m2 | Oral |